Kiromic Stock Analysis

KRBP -  USA Stock  

USD 1.13  0.16  12.40%

The big decline in price over the last few months for Kiromic Biopharmamay raise some interest from insiders. The stock closed today at a share price of 1.13 on 188,764 in trading volume. The company management teams failed to add value to investors and positioning the firm supply of money to exploit market volatility in December. However, diversifying your holdings with Kiromic Biopharma or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 7.87. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Kiromic Biopharma partners.
Please see Stocks Correlation.

Kiromic Stock Analysis 

 
Refresh
The Kiromic Biopharma stock analysis report makes it easy to digest most publicly released information about Kiromic Biopharma and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Kiromic Stock analysis module also helps to analyze the Kiromic Biopharma price relationship with some important fundamental indicators such as market cap and management efficiency.

Kiromic Stock Analysis Notes

About 23.0% of the company outstanding shares are owned by corporate insiders. The book value of Kiromic Biopharma was now reported as 0.66. The company recorded a loss per share of 2.24. Kiromic Biopharma had not issued any dividends in recent years. Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas. Kiromic Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 19 people. To find out more about Kiromic Biopharma contact the company at 832 968 4888 or learn more at https://www.kiromic.com.

Kiromic Biopharma Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Kiromic Biopharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Kiromic Biopharma or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Kiromic Biopharma generated a negative expected return over the last 90 days
Kiromic Biopharma has high historical volatility and very poor performance
Kiromic Biopharma may become a speculative penny stock
Kiromic Biopharma has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (14.88 M).
Kiromic Biopharma currently holds about 3.07 M in cash with (9.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.2.
Kiromic Biopharma has a poor financial position based on the latest SEC disclosures
Roughly 23.0% of the company outstanding shares are owned by corporate insiders
Latest headline from www.globenewswire.com: Diamond Equity Research Initiates Coverage on Kiromic BioPharma, Inc. NASDAQ - GlobeNewswire

Kiromic Biopharma Upcoming and Recent Events

Earnings reports are used by Kiromic Biopharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Kiromic Biopharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report30th of March 2022
Next Earnings Report13th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End30th of March 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Kiromic Biopharma SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Kiromic Biopharma prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Kiromic Biopharma investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Kiromic Biopharma specific information freely available to individual and institutional investors to make a timely investment decision.
13th of January 2022
Unclassified Corporate Event
View
21st of December 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
10th of December 2021
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
7th of December 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
24th of November 2021
Financial Statements and Exhibits. Other Events. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
View
19th of November 2021
Financial Statements and Exhibits. Other Events
View
16th of November 2021
Other Events
View
29th of October 2021
Financial Statements and Exhibits. Other Events
View

Kiromic Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Kiromic Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kiromic Biopharma backward and forwards among themselves. Kiromic Biopharma's institutional investor refers to the entity that pools money to purchase Kiromic Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Kepos Capital LpCommon Shares767 K2.4 M
Sabby Management LlcCommon Shares478.1 K1.5 M
1492 Capital Management LlcCommon Shares434.4 K1.3 M
Citadel Advisors LlcCall Options336 KM
Vanguard Group IncCommon Shares295.3 K906 K
Intellectus Partners LlcCommon Shares98.8 K303 K
Zeke Capital Advisors LlcCommon Shares56.9 K175 K
Lpl Financial LlcCommon Shares52.8 K162 K
Citadel Advisors LlcPut Options34.1 K105 K
Note, although Kiromic Biopharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Kiromic Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 23.77 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Kiromic Biopharma's market, we take the total number of its shares issued and multiply it by Kiromic Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Kiromic Profitablity

Kiromic Biopharma's profitability indicators refer to fundamental financial ratios that showcase Kiromic Biopharma's ability to generate income relative to its revenue or operating costs. If, let's say, Kiromic Biopharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Kiromic Biopharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Kiromic Biopharma's profitability requires more research than a typical breakdown of Kiromic Biopharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(2.23) (2.41) 
Return on Average Equity(3.31) (3.57) 
Return on Invested Capital(19.98) (20.51) 

Management Efficiency

The entity has return on total asset (ROA) of (180.54) % which means that it has lost $180.54 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (425.08) %, meaning that it created substantial loss on money invested by shareholders. Kiromic Biopharma management efficiency ratios could be used to measure how well kiromic biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 19th of January 2022, Return on Average Assets is likely to drop to -2.41. In addition to that, Return on Average Equity is likely to drop to -3.57. As of 19th of January 2022, Total Liabilities is likely to drop to about 1.4 M. In addition to that, Current Liabilities is likely to drop to about 1.4 M
Last ReportedProjected for 2022
Book Value per Share 2.90  3.13 
Enterprise Value over EBIT(2.70) (2.92) 
Enterprise Value over EBITDA(2.92) (3.15) 
Price to Book Value 4.92  4.89 
Tangible Assets Book Value per Share 3.27  3.53 
Enterprise Value55.6 M55.2 M
Tangible Asset Value14.8 M15.9 M

Technical Drivers

As of the 19th of January, Kiromic Biopharma secures the risk adjusted performance of (0.030069), and Mean Deviation of 5.62. Kiromic Biopharma technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We have analyzed nineteen technical drivers for Kiromic Biopharma, which can be compared to its peers in the industry. Please verify Kiromic Biopharma variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Kiromic Biopharma is priced some-what accurately, providing market reflects its recent price of 1.13 per share. Given that Kiromic Biopharma is a hitting penny stock territory we strongly suggest to closely look at its total risk alpha.

Kiromic Biopharma Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Kiromic Biopharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Kiromic Biopharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target. View also all equity analysis or get more info about bollinger bands overlap studies indicator.

Kiromic Biopharma Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kiromic Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kiromic Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Kiromic Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Kiromic Biopharma Predictive Daily Indicators

Kiromic Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Kiromic Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Kiromic Biopharma Forecast Models

Kiromic Biopharma time-series forecasting models is one of many Kiromic Biopharma's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Kiromic Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Kiromic Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Kiromic Biopharma stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Kiromic shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Kiromic Biopharma. By using and applying Kiromic Stock analysis, traders can create a robust methodology for identifying Kiromic entry and exit points for their positions.
Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas. Kiromic Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 19 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Kiromic Biopharma to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Cryptocurrency Center Now

   

Cryptocurrency Center

Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
All  Next Launch Module
Please see Stocks Correlation. Note that the Kiromic Biopharma information on this page should be used as a complementary analysis to other Kiromic Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for Kiromic Stock analysis

When running Kiromic Biopharma price analysis, check to measure Kiromic Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiromic Biopharma is operating at the current time. Most of Kiromic Biopharma's value examination focuses on studying past and present price action to predict the probability of Kiromic Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kiromic Biopharma's price. Additionally, you may evaluate how the addition of Kiromic Biopharma to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Is Kiromic Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiromic Biopharma. If investors know Kiromic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiromic Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kiromic Biopharma is measured differently than its book value, which is the value of Kiromic that is recorded on the company's balance sheet. Investors also form their own opinion of Kiromic Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Kiromic Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiromic Biopharma's market value can be influenced by many factors that don't directly affect Kiromic Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kiromic Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Kiromic Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiromic Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.